Business Context and Reporting Period
Company: Stryker Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2001
Business Overview: Stryker operates in two primary reportable segments: Orthopaedic Implants (reconstructive and trauma products) and MedSurg Equipment (surgical instruments, endoscopic systems, and patient care equipment). The company also reports Physical Therapy Services and corporate administration under "Other."
Key Financial Metrics
| Metric | Q1 2001 | Q1 2000 |
|---|---|---|
| Net Sales | $634.2 million | $562.1 million |
| Gross Profit | $401.9 million | $360.5 million |
| Gross Margin | 63.4% | 64.1% |
| Net Earnings | $64.1 million | $51.8 million |
| Diluted EPS | $0.32 | $0.26 |
| Operating Cash Flow | $74.6 million | $28.3 million |
| Total Debt (Long-term + Current) | $960.1 million | $1,012.5 million (Dec 2000) |
| Cash and Equivalents | $61.1 million | $54.0 million (Dec 2000) |
| Working Capital | $415.1 million | $379.6 million (Dec 2000) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 13% year-over-year, driven by a 12% increase in unit volume, 2% price increases, and 1% from acquisitions. This growth was partially offset by a 3% negative impact from foreign currency exchange rates.
- Segment Performance:
- Orthopaedic Implants: Sales rose 7% to $359.6 million (12% excluding currency).
- MedSurg Equipment: Sales rose 19% to $231.0 million (21% excluding currency).
- Physical Therapy Services: Sales rose 30% to $43.6 million.
- Profitability: Net earnings increased 24% to $64.1 million. The effective tax rate decreased to 33.0% from 34.0% due to manufacturing tax benefits in Ireland and Puerto Rico.
- Expense Classification: Gross margin percentage decreased slightly (63.4% vs 64.1%) primarily due to a change in accounting treatment where freight revenue is now recorded in net sales (previously offset against cost of sales) and certain shipping costs were reclassified from SG&A to Cost of Sales.
- Debt Reduction: Total debt declined by $52.4 million during the quarter due to repayments exceeding new borrowings.
Guidance, Outlook, and Risks
- Liquidity: Management believes cash on hand and anticipated operating cash flows are sufficient to fund operations, capital requirements, and debt repayments. The company has $275.0 million of additional borrowing capacity available.
- Restructuring: Remaining headcount reductions related to the Howmedica acquisition and other restructuring initiatives are expected to be completed in 2001. Facility closures and contractual obligations extend to 2008.
- Accounting Changes: The company adopted FASB Statement No. 133 regarding derivative instruments and hedging activities on January 1, 2001. Approximately 63% of variable-rate debt is hedged via interest rate swaps.
- Risks: Forward-looking statements are subject to risks including changes in economic conditions affecting demand, foreign exchange market fluctuations, and competitive environment changes. Foreign currency translation adjustments reduced the value of international net assets by $28.4 million in Q1 2001.
Investor Verification Checklist
- Freight Revenue Impact: Verify the long-term impact of reclassifying freight revenue and shipping costs on gross margin comparisons.
- Foreign Currency Exposure: Assess the sensitivity of international sales and net asset valuations to currency fluctuations, given the $18.8 million unfavorable impact on sales and $28.4 million translation loss in Q1.
- Howmedica Integration: Monitor the completion of remaining workforce reductions and facility closures associated with the 1998 Howmedica acquisition.
- Debt Maturities: Review the schedule for current maturities of long-term debt, which are projected to increase to $165.9 million in 2003 and $204.3 million in 2004.
- Derivative Hedging: Confirm the effectiveness of interest rate swaps and foreign currency hedges in mitigating financial statement volatility under FASB 133.